When Will Mounjaro Come in Pill Form — and What to Do in the Meantime

Why Mounjaro is still injection-only, and what Eli Lilly's research means for the UK

Tirzepatide works by activating two gut-hormone receptors simultaneously, a mechanism that makes oral delivery significantly more complicated than for single-pathway GLP-1 medicines. Getting enough of the drug across the gut wall requires specialist formulation technology, the same challenge that took semaglutide decades to solve before oral Ozempic (for diabetes) and then the Wegovy tablet (for weight management) became possible.

Eli Lilly has confirmed it is exploring an oral tirzepatide candidate, and early-phase clinical research is ongoing. However, the regulatory process in the UK is sequential: clinical trials must report, a licensing dossier must be submitted to the MHRA, and the agency then reviews it, a process that can take years after trial completion. As of summer 2026, no MHRA submission for oral tirzepatide has been approved, and no confirmed timeline exists. The full clinical picture of tirzepatide as a treatment, including what the trials have shown so far, is worth understanding if you're still making up your mind.

What this means practically: if you're holding off on treatment in the hope that a Mounjaro pill will arrive within the next six to twelve months, there is no published evidence to support that timeline. That's not a criticism of Lilly, it's just the honest regulatory picture.

The oral weight-loss option that does exist in the UK right now

On 11 June 2026, the MHRA approved Wegovy tablets (oral semaglutide co-formulated with an absorption enhancer) making the UK the first country in Europe to license an oral GLP-1 for weight management. It's a meaningful development, and it changes the practical calculation for anyone who specifically wants to avoid injections.

The tablet is taken once daily, first thing in the morning, on an empty stomach with a small amount of plain water, then a wait of at least 30 minutes before food, coffee, or any other medicine. The licensed dosing ladder starts at 1.5mg and escalates through 4mg and 9mg to a 25mg maintenance dose, with at least a month at each level. In the OASIS 4 phase-3 trial, participants saw an average weight reduction of around 13.6% over 64 weeks, rising to roughly 17% among those who stayed fully adherent throughout. Those numbers are from a controlled trial setting, your own result depends on many factors your prescriber will discuss with you.

If you want to understand whether an oral tirzepatide option is available separately, that page sets out the current research position in more detail. For now, the Wegovy tablet is the only oral prescription weight-loss medicine the MHRA has approved. It is not Mounjaro, and it works on a single receptor rather than the dual pathway tirzepatide uses, but it is real, it is licensed, and it is available.

Deciding whether to start injectable Mounjaro now or wait

This is the decision most people asking this question are actually trying to make. The factors worth considering are clinical, not just personal preference.

Injectable Mounjaro has a substantial evidence base. SURMOUNT-1 (a 72-week trial involving 2,539 adults with obesity) reported an average body-weight reduction of around 20 to 21% at the 15mg dose, and the SURMOUNT-5 head-to-head trial published in the New England Journal of Medicine in 2025 found tirzepatide produced greater average weight loss than semaglutide 2.4mg. NICE recommended tirzepatide for NHS use in December 2024 (technology appraisal TA1026) for adults with a BMI of 35 or above and at least one weight-related condition, though private treatment has different eligibility criteria.

Against that, if needles are a genuine barrier for you (not just a mild preference) then waiting for or switching to an oral option is a real conversation. The injectable remains the only tirzepatide treatment available, and the evidence for its results is stronger than for anything currently in a pill. A prescriber can look at your health history, your weight-loss goals, and your practical circumstances, and give you a view that a product comparison page cannot. You can learn more about how Mounjaro works and who it's suitable for before making that call, and if you've noticed joint discomfort while using it, our page on whether Mounjaro can cause knee pain covers what the evidence currently says.

Cost, access, and what to check before you start anything

Cost is part of the calculation too. The price of injectable Mounjaro on the private market has changed since Eli Lilly adjusted UK list prices in September 2025, with typical private prices now ranging roughly £149 to £375 per month depending on dose and provider. How those figures compare to an oral alternative (and what each price actually includes in terms of consultation, aftercare, and delivery) matters more than the headline number. A breakdown of what private Mounjaro costs and why prices vary is on the Mounjaro cost page, if that's useful context.

Whatever route you're considering, it must go through a prescription. Both Mounjaro and Wegovy tablets are prescription-only medicines: a prescriber reviews your medical history, confirms suitability, and oversees any dose changes. That's not a formality, it's where patient safety actually lives. The MHRA has a Yellow Card reporting service for anyone who encounters suspect sellers or experiences unexpected side effects, and it's worth knowing it exists.

If you'd like a prescriber to look at your situation and discuss the options that are actually available to you today, you can check your eligibility with a free consultation at any point.